TYPE 2 DIABETES MELLITUS
Condition Identity
Type 2 Diabetes Mellitus
Chronic metabolic disorder
Insulin resistance with relative insulin deficiency
Most common form of diabetes, accounting for 90-95% of all cases
Epidemiology
Risk Factors
- Obesity (BMI >25 kg/mยฒ in Asians; >30 kg/mยฒ in others)
- Physical inactivity
- Family history of T2DM (first-degree relative)
- Impaired fasting glucose or impaired glucose tolerance
- Gestational diabetes or delivery of infant >4 kg
- Polycystic ovary syndrome (PCOS)
- Age >45 years
- Hypertension
- Dyslipidaemia (low HDL, high triglycerides)
- Ethnicity (South Asian, African, Hispanic, Pacific Islander)
- Acanthosis nigricans
- Metabolic syndrome
- Chronic steroid use or antipsychotic therapy
Signs & Symptoms
- Acanthosis nigricans (neck, axillae)
- Obesity or central adiposity (waist circumference elevated)
- Hypertension
- Peripheral neuropathy signs (reduced vibration, proprioception, monofilament test)
- Reduced or absent ankle reflexes
- Diabetic foot changes (callus, ulceration, Charcot foot)
- Retinal changes on fundoscopy
- Signs of dyslipidaemia (xanthelasma, xanthomata)
- May be completely asymptomatic in early stages
- Polyuria (frequent urination)
- Polydipsia (excessive thirst)
- Polyphagia (increased hunger) โ often absent in T2DM
- Unexplained weight loss
- Blurred vision
- Fatigue and lethargy
- Recurrent infections (skin, urinary tract, vaginal candidiasis)
- Slow-healing wounds
- Paraesthesia or numbness in hands and feet (early neuropathy)
- Erectile dysfunction in males
Complications
DOWNSTREAM CLINICAL COMPLICATIONS & SEQUELAE
- Diabetic retinopathy (leading cause of preventable blindness)
- Diabetic nephropathy (leading cause of end-stage renal disease)
- Peripheral neuropathy
- Autonomic neuropathy (gastroparesis, orthostatic hypotension, erectile dysfunction)
- Diabetic foot ulceration and Charcot arthropathy
- Cardiovascular disease (ischaemic heart disease, stroke, peripheral arterial disease)
- Hyperosmolar hyperglycaemic state (HHS)
- Hypoglycaemia (from pharmacological treatment)
- Non-alcoholic fatty liver disease (NAFLD/NASH)
- Increased susceptibility to infections
- Depression and anxiety
Diagnostic Criteria
DIAGNOSTIC RED FLAGS & EMERGENCY RULE-OUTS
- HbA1c >86 mmol/mol (>10%)
- Acute hyperosmolar hyperglycaemic state (HHS)
- Severe hypoglycaemia with loss of consciousness
- Diabetic ketoacidosis (rare in T2DM)
- Rapidly deteriorating renal function
- New visual loss
- Fasting plasma glucose โฅ7.0 mmol/L (126 mg/dL)
- 2-hour plasma glucose โฅ11.1 mmol/L during 75 g OGTT
- HbA1c โฅ48 mmol/mol (6.5%) โ confirmed on a second test if asymptomatic
- Random plasma glucose โฅ11.1 mmol/L with symptoms of hyperglycaemia
| Condition | Distinguishing Features | Recommended Workup |
|---|---|---|
| Type 1 diabetes mellitus โ | โ | โ |
| Latent autoimmune diabetes in adults (LADA) | โ | โ |
| Maturity-onset diabetes of the young (MODY) | โ | โ |
| Secondary diabetes (Cushing syndrome, acromegaly, pancreatitis) | โ | โ |
| Gestational diabetes mellitus โ | โ | โ |
| Drug-induced hyperglycaemia (steroids, antipsychotics) | โ | โ |
Investigations
Bedside Tests
- Capillary blood glucose (fingerprick)
- Blood pressure
- BMI and waist circumference
- Urine dipstick (glucose, protein, ketones)
First-Line Diagnostic Tests
- Fasting plasma glucose
- HbA1c
- Oral glucose tolerance test (OGTT) if borderline
- Urine albumin:creatinine ratio (ACR)
- eGFR and serum creatinine
- Fasting lipid profile
- Liver function tests
- Thyroid function tests (to exclude thyroid dysfunction)
- ECG (baseline cardiovascular risk assessment)
Confirmatory & Specialized Tests
- C-peptide levels (to exclude LADA/T1DM)
- Islet cell antibodies (anti-GAD, anti-IA2) if LADA suspected
- Genetic testing if MODY suspected
Continuous & Serial Monitoring
- HbA1c every 3โ6 months until stable, then every 6 months
- Annual urine ACR
- Annual eGFR
- Annual dilated retinal examination
- Annual foot examination (10-g monofilament, vibration, pulses)
- Annual fasting lipid profile
- Annual blood pressure
Nonpharmacological Management
- Structured diabetes self-management education (DSME)
- Medical nutrition therapy (MNT): low-glycaemic index diet, carbohydrate counting
- Physical activity: 150 minutes/week of moderate aerobic exercise + resistance training
- Weight loss (5โ10% body weight reduction significantly improves glycaemic control)
- Smoking cessation
- Alcohol moderation
- Foot care education (daily inspection, appropriate footwear)
- Regular blood glucose self-monitoring
- Bariatric surgery (if BMI >35 kg/mยฒ with inadequate glycaemic control)
Monitoring
- HbA1c at target (typically <53 mmol/mol / 7%) within 3โ6 months
- Fasting glucose 4โ7 mmol/L
- Postprandial glucose <8.5 mmol/L at 2 hours
- No symptomatic hypoglycaemia
- Stable or improving renal function
- HbA1c every 3โ6 months (stable: 6 monthly)
- eGFR and urine ACR annually
- Fasting lipid profile annually
- LFTs annually (or more frequently if on hepatotoxic agents)
- 3 months after treatment initiation for HbA1c check
- Annual diabetes review: eyes, feet, kidneys, cardiovascular risk, mental health, medications
- Refer to ophthalmology at diagnosis and annually
- HbA1c persistently above target despite optimal oral therapy
- eGFR declining below 30 mL/min
- Macroalbuminuria or rapid proteinuria progression
- Symptomatic neuropathy or foot complications
- Cardiovascular event
- T2DM is a chronic progressive condition but can enter remission with significant weight loss (DiRECT trial data)
- Remission defined as HbA1c <48 mmol/mol without glucose-lowering medication for >3 months
Prevention
- Annual influenza vaccination
- Pneumococcal vaccine (PPSV23 and PCV13)
- Hepatitis B vaccination if not previously immunised
- Early identification and treatment of prediabetes
- Weight loss of 5โ7% reduces progression from prediabetes to T2DM by 58% (DPP trial)
- Metformin for high-risk individuals with prediabetes
- Maintain healthy BMI
- Regular physical activity
- Mediterranean or low-glycaemic diet
- Limit refined carbohydrates and added sugars
- Alcohol moderation
- Smoking cessation
- Hypoglycaemia recognition and treatment
- Sick-day rules
- Foot care and wound monitoring
- Blood glucose self-monitoring technique
- When to seek emergency care
EMERGENCY RETURN PRECAUTIONS
- Severe hypoglycaemia or loss of consciousness
- Blood glucose >20 mmol/L unresponsive to self-management
- Signs of HHS: extreme thirst, confusion, very high glucose without ketones
- Foot infection, ulceration, or rapidly spreading cellulitis
- Chest pain, dyspnoea, or sudden neurological deficit
Prognosis
T2DM is a chronic progressive condition. With optimal glycaemic control and cardiovascular risk management, complications can be significantly delayed or prevented. Life expectancy may be reduced by approximately 6 years without optimal management. Bariatric surgery and intensive lifestyle interventions have demonstrated sustained remission in selected patients.
Referral Criteria
ICU & EMERGENCY RESUSCITATION INDICATIONS
- HHS with altered consciousness or haemodynamic instability
- DKA (rare in T2DM but possible)
- Severe infection with multiorgan involvement
HOSPITAL ADMISSION INDICATIONS
- Hyperosmolar hyperglycaemic state (HHS)
- Severe hypoglycaemia with loss of consciousness
- Uncontrolled hyperglycaemia with dehydration
- Diabetic foot infection with systemic sepsis or osteomyelitis
- Acute cardiovascular or renal complications
- Endocrinology: complex diabetes, suspected LADA/MODY, insulin initiation in primary care unfamiliar setting
- Ophthalmology: annual retinal screening, new visual symptoms
- Nephrology: eGFR <30, rapid deterioration, significant proteinuria
- Podiatry: any foot complication, high-risk foot
- Cardiology: established CVD or high risk
- Dietitian: medical nutrition therapy
- Psychologist: diabetes distress, depression
All content in Medobo is for educational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional and local institutional protocols before administering medication or initiating treatment.